Blueprint Medicines Corporation (BPMC)

43,52 -2,00 (-4,39%) Alla chiusura: 04:00PM EDT

Blueprint Medicines Corporation

45 Sidney Street
Cambridge, MA 02139
United States
617 374 7580
https://www.blueprintmedicines.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 602

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Kathryn Haviland	Pres, CEO & Director	786,39k	249,04k	1976
Mr. Alexis A. Borisy A.M.	Co-Founder & Director	46,64k	N/D	1972
Mr. Michael Landsittel	Chief Financial Officer	679,05k	N/D	1972
Dr. Percy H. Carter M.B.A., Ph.D.	Chief Scientific Officer	761,15k	N/D	1971
Dr. Fouad Namouni M.D.	Pres of R&D	986,52k	N/D	1969
Ms. Christina Rossi	Chief Operating Officer	N/D	N/D	1976
Dr. Christopher K. Murray	Sr. VP of Technical Operations	N/D	N/D	1963
Jenna Cohen	Sr. Director & Head of Investor Relations	N/D	N/D	N/D
Ms. Tracey L. McCain Esq.	Exec. VP, Chief Legal & Compliance Officer and Sec.	N/D	N/D	1968
Ms. Debra Durso-Bumpus	Chief People Officer	N/D	N/D	1970

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Blueprint Medicines Corporation al 1 febbraio 2023 è 7. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 10; diritti degli azionisti: 7; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.